Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Seer (Nasdaq: SEER), a company focused on proteomic insights, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seer (Nasdaq: SEER), a company focused on proteomic insights, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management will engage in a fireside chat on September 9th at 12:20 PM ET.
Investors can access the presentation through a live webcast on the Investor section of Seer's website at investor.seer.bio. An archived version of the presentation will be made available after the conference.
Details
News Market Reaction – SEER
On Aug 27, the first trading day after this news, SEER closed 0.96% below the previous close.
Data tracked by StockTitan Argus for the Aug 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.
Seer’s management is scheduled to participate in a fireside chat on Tuesday, September 9th at 12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.
About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges that conventional methods have failed to overcome. Traditional proteomic technologies have historically struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
Media Contact:
Consort Partners
pr@seer.bio
Investor Inquiries:
Carrie Mendivil
investor@seer.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.